Spyre Therapeutics (SYRE) announced Spyre has been added to the Nasdaq Biotechnology Index effective prior to market open, Monday, December 23.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SYRE:
- TD says Spyre has ‘superior TL1A program’ after Teva data
- Spyre Therapeutics weakness after Teva data a buying opportunity, says BTIG
- Spyre Therapeutics initiated with a Hold at JonesResearch
- Spyre Therapeutics announces first participants dosed in Phase 1 trial
- Spyre Therapeutics 7.275M share Spot Secondary priced at $27.50
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
